| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00198-003-1508-Y |
| P953 | full work available at URL | http://link.springer.com/content/pdf/10.1007/s00198-003-1508-y.pdf |
| http://link.springer.com/article/10.1007/s00198-003-1508-y/fulltext.html | ||
| http://link.springer.com/content/pdf/10.1007/s00198-003-1508-y | ||
| P698 | PubMed publication ID | 14530912 |
| P5875 | ResearchGate publication ID | 5542553 |
| P50 | author | Willi Sauerbrei | Q90910842 |
| P2093 | author name string | M. Palmer | |
| M. Schumacher | |||
| I. Fogelman | |||
| A. Stewart | |||
| D. Serin | |||
| G. M. Blake | |||
| R. Blamey | |||
| W. Wilpshaar | |||
| P2860 | cites work | Drug-induced bone loss | Q34091986 |
| Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer | Q34162335 | ||
| Osteoporosis overview | Q34165071 | ||
| Gonadotropin-releasing hormone agonists and the skeleton | Q35958935 | ||
| Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer | Q35981774 | ||
| Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results | Q36711887 | ||
| The effects of oestrogen deficiency on the skeleton and its prevention | Q41210358 | ||
| Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications | Q41455809 | ||
| Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian | Q44253498 | ||
| Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study | Q44253501 | ||
| Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group | Q46315882 | ||
| Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation | Q46462191 | ||
| Age, time since menopause, and body parameters as determinants of female spinal bone mass: a mathematical model. | Q52446865 | ||
| Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. | Q53352452 | ||
| Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration | Q71008862 | ||
| Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment | Q71130417 | ||
| Standardization of spine BMD measurements | Q71207833 | ||
| Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients | Q73437638 | ||
| Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 r | Q74000615 | ||
| Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy | Q74216559 | ||
| Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer | Q74545184 | ||
| Bone loss induced by cancer treatment and its management | Q77312714 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluorouracil | Q238512 |
| methotrexate | Q422232 | ||
| P304 | page(s) | 1001-1006 | |
| P577 | publication date | 2003-10-03 | |
| P1433 | published in | Osteoporosis International | Q7107640 |
| P1476 | title | Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) | |
| P478 | volume | 14 |
| Q38001377 | A prospective model of care for breast cancer rehabilitation: bone health and arthralgias. |
| Q46417627 | Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy |
| Q37157596 | Adverse bone effects during pharmacological breast cancer therapy |
| Q37872146 | Aging and osteoporosis in breast and prostate cancer |
| Q37054153 | Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? |
| Q35048224 | Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer |
| Q38065098 | Bone homeostasis and breast cancer: implications for complex therapy and the maintenance of bone integrity |
| Q35779327 | Bony non-union in a patient receiving androgen deprivation therapy for prostate cancer |
| Q37153908 | Breast cancer in young women and its impact on reproductive function |
| Q49211720 | Cancer Treatment and Bone Health |
| Q36410640 | Cancer treatment-related bone loss: a review and synthesis of the literature |
| Q36218199 | Cathepsin L targeting in cancer treatment. |
| Q43107263 | Combination of radiological and biochemical methods to assess bone mineral density of mandible in fully edentulous patients after chemotherapy: a 5-year prospective study |
| Q47104810 | Cyclophosphamide causes osteoporosis in C57BL/6 male mice: suppressive effects of cyclophosphamide on osteoblastogenesis and osteoclastogenesis |
| Q34999480 | Fracture in asian women with breast cancer occurs at younger age |
| Q36661462 | Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover |
| Q36360338 | Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women |
| Q37830052 | Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates |
| Q34004925 | Increased fracture rate in women with breast cancer: a review of the hidden risk |
| Q37116142 | Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer |
| Q37623827 | Luteinizing hormone-releasing hormone (LHRH) agonists in the treatment of breast cancer |
| Q38619529 | Management of bone disease in women after breast cancer |
| Q38090917 | Management of cancer treatment-induced bone loss |
| Q36906736 | Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club |
| Q36243750 | Management of menopausal symptoms in patients with breast cancer: an evidence-based approach |
| Q34617936 | NCCN Task Force Report: Bone Health in Cancer Care |
| Q57108686 | Osteoporosis and musculoskeletal complications related to therapy of breast cancer |
| Q26775765 | Prevention and treatment of bone fragility in cancer patient |
| Q34613485 | Prevention of bone metastases and management of bone health in early breast cancer. |
| Q36796392 | Regulatory pathways associated with bone loss and bone marrow adiposity caused by aging, chemotherapy, glucocorticoid therapy and radiotherapy |
| Q54643065 | Runx2 in human breast carcinoma: its potential roles in cancer progression |
| Q38152661 | Skeletal manifestations of treatment of breast cancer on premenopausal women |
| Q46735606 | Treatment recommendations for the use of bone-targeted agents in 2011?report from the 6th Annual Bone and the Oncologist New Updates meeting. |
| Q51514495 | Use of bisphosphonates and risk of breast cancer. |
| Q36235537 | Use of goserelin in the treatment of breast cancer |
| Q37123420 | Zoledronic acid for cancer therapy--induced and postmenopausal bone loss |
| Q34414177 | Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. |
| Q37121724 | Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer |
Search more.